Work

Phase IB Study of Vemurafenib in Combination with the Mek Inhibitor, GDC-0973, in Patients (PTS) with Unresectable or Metastatic BRAFV600 Mutated Melanoma (BRIM7)

Year: 2012

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/s0923-7534(20)34336-2

Authors: R. Gonzalez, A. Ribas, A. Daud, A. Pavlick, T.F. Gajewski, I. Puzanov, M.S.L. Teng, I. Chan, N.W. Choong, G. McArthur

Institutions: University of Colorado Anschutz, UCLA Jonsson Comprehensive Cancer Center, University of California, San Francisco, New York University, University of Chicago, Vanderbilt University, Vanderbilt University Medical Center, Genentech, Peter MacCallum Cancer Centre

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2998895464

FWCI: 2.098

Cites:

Cited by: 21

Related to: 10